MCL1 and acute myeloid leukemia: We demonstrate for the first time that small molecule BH3-mimetics directly targeting BCL-2 and MCL1 can potently suppress human AML, with limited toxicity to normal human hematopoietic progenitors, potentially overcoming one of the major limitations from the use of cytotoxic drugs.